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ABSTRACT
Over the past few years, small ubiquitin-like
modifier (SUMO) modification has emerged as an
important regulator of diverse pathways and
activities including protein localization and tran-
scriptional regulation. We identified a consensus
sumoylation motif (IKEE), located within the
N-terminal activation domain of the ATF7 transcrip-
tion factor and thus investigated the role of this
modification. ATF7 is a ubiquitously expressed
transcription factor, homologous to ATF2, that
binds to CRE elements within specific promoters.
This protein is able to heterodimerize with Jun or
Fos proteins and its transcriptional activity is
mediated by interaction with TAF12, a subunit of
the general transcription factor TFIID. In the present
article, we demonstrate that ATF7 is sumoylated
in vitro (using RanBP2 as a E3-specific ligase) and
in vivo. Moreover, we show that ATF7 sumoylation
affects its intranuclear localization by delaying
its entry into the nucleus. Furthermore, SUMO
conjugation inhibits ATF7 transactivation activity
by (i) impairing its association with TAF12 and
(ii) blocking its binding-to-specific sequences
within target promoters.
INTRODUCTION
In eukaryotic cells, post-translational protein modiﬁca-
tions are crucial mechanisms to regulate protein function.
Polypeptide conjugation to substrate proteins is one of
these known mechanisms. Ubiquitin and ubiquitin-like
proteins are small polypeptides of about 8–11kDa that
covalently modify various intracellular proteins. Among
these, the small ubiquitin-related modiﬁers (SUMO-1–4)
are covalently linked as a 93–97 amino-acid polypeptides
to speciﬁc target lysine residues (1–4). Sumoylation is
catalyzed by an enzymatic machinery analogous to that of
ubiquitin-modiﬁcation (2) and usually takes place at sites
matching the sequence fKXE (where f stands for I, L or
V and X for any amino acid residue). In addition to this
core consensus motif, an extended sequence encompassing
several acidic residues clustered within the 10-amino-acid
region located immediately downstream has been recently
described to play an important role in determining
the eﬃciency of substrate sumoylation (5). Sumoylation
depends on an activating SAE1/SAE2 E1-enzyme hetero-
dimer, the SUMO conjugating enzyme Ubc9 and recently
identiﬁed E3 SUMO ligases. In contrast to ubiquitination
that targets the conjugated proteins to 26S proteasome-
mediated degradation, the biological consequences
of SUMO modiﬁcation include nuclear targeting, the
formation of subnuclear structures, the regulation of
transcriptional activities and the control of protein
stability (1,4,6).
The family of ATF7 (formerly ATFa) transcription
factors, structurally and functionally related to ATF2, is
composed of at least three members (ATF7-1, 2, 3) (7,8)
translated from alternatively spliced messengers issued
from a single gene (9). Although the three ATF7 isoforms
diﬀer by the presence of small motifs within their
N-terminal region, they exhibit indistinguishable activ-
ities. Their transcriptional activation domain has been
delineated within the N-terminal part of the protein and
shown to include a critical zinc-binding element and two
conserved threonine residues (T51 and T53, correspond-
ing to the T69 and T71 homologs in ATF2) (10,11).
This region, together with sequences located in the
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their interaction with the adenovirus E1a oncoprotein (8).
ATF7, like ATF2, can also associate with c-Jun or c-Fos
proteins through their C-terminal leucine-zipper (b-ZIP)
region. While ATF proteins usually bind as homodimers
to ATF/CRE promoter elements, they also can bind TRE
sequences if heterodimerized with members of the Jun
family (10,12). ATF7 proteins also strongly interact with
the JNK2 protein kinase (13), although they do not
constitute substrates for this kinase but rather serve as a
JNK2-docking site for ATF7-associated partners like
JunD, (11). Collectively, these data suggest that ATF7
proteins play important functions early in cell signaling.
The transcriptional activity of ATF7 is potentiated by
the expression of TAF12, a subunit of TFIID, through
direct interactions implicating the N-terminal domains of
the two proteins, as well as the TAF12 histone fold
domain (14). TAF4, the HFD-containing protein partner
of TAF12 within TFIID also interacts with ATF7 and
thereby competes for the coactivator eﬀect of TAF12.
Interestingly its paralog TAF4b, that plays a role in
fertility does not (14,15). In fact, TAF4 has been shown to
play a central role in multiple signaling pathways by
competing with TAF4b (16) for the presence of various
transcription factors, among these CREB, SP1, RAR and
ATF7 (17).
In the present study, we investigate the modiﬁcation of
ATF7 protein by SUMO-1. We demonstrate that ATF7 is
sumoylated in human cells and that this modiﬁcation
delays its nuclear localization and therefore inhibits ATF7
transcriptional activity by impairing its interaction with
TAF12 in TFIID.
MATERIALS AND METHODS
Expression vectors
The recombinant human ATF7 isoform used in the
present study is ATF7-1 and will be referred as ATF7,
with coordinates corresponding to the amino acid
numbering of the largest protein (ATF7-3, 494
residues) (14).
The vectors pG4-ATF7-1 recombinant and correspond-
ing derivatives encode the DNA-binding domain of the
yeast Gal4 protein fused to the wild type (wt) or mutated
human ATF7-1 polypeptide, as described (10). The
cDNAs of ATF7-1 and derivatives, and human ATF2,
RanBP2iFG have also been inserted into the pXJ or
pXJ-HA vectors, under the control of the CMV promoter
(18), generating the px-ATF7 series and px-hsATF2,
px-RanBP2iFG, respectively.
The (17m5)-TK-Luc reporter (19) contains the lucifer-
ase gene, driven by the thymidine kinase promoter and ﬁve
Gal4 binding sites (see Figure 5A).
The pATF-GFP was constructed by cloning the
sequence encoding the N-terminal portion of ATF7
(amino acids 1–250) into an engineered XhoI site immedi-
ately 30 to the start codon of GFP in pXRGG (20),
a derivative of pGreenLantern (Life Technologies). This
plasmid encodes a fusion protein containing the ATF7
activation domain, followed by the hormone-response
element of the rat glucocorticoid receptor and by the
GFP. pGST-RanBP2 FG was a gift of Anne Dejean.
Point-mutations and deletions were created in the
ATF7-1 moiety by oligonucleotide-directed mutagenesis
using the Pfu-DNA polymerase (21), PCR-ampliﬁcation
of appropriate DNA fragments, or restriction fragment
deletion. All constructions were veriﬁed by DNA
sequencing.
Cells,transfection andextract preparation
HeLa-SUMO cells, a gift from P. O’Hare (22), were grown
as monolayers in Dulbecco medium supplemented with
glucose (1g/l) and 10% fetal calf serum. Huvec-c cells
were grown in Ham’s F12K medium supplemented with
2mM L-glutamine, 0.1mg/ml heparin, 0.05mg/ml
endothelial cell growth supplement (ECGS), and 10%
FBS. Cells were transfected with recombinant plasmids,
8h after plating, using Transfectin reagent (Bio-Rad,
USA), with the amounts of recombinant DNA indicated
in the ﬁgure legends. After 36h, cells were harvested in
phosphate-buﬀered saline (PBS) and resuspended in RIPA
buﬀer (150mM NaCl, 10mM Tris-HCl, pH 7.2, 0.1%
SDS, 1% Triton X-100, 1% deoxycholate, 5mM EDTA,
0.4mM PMSF, 2.5ng/ml each of leupeptin, pepstatin,
aprotinin, antipain and chymostatin). After 30min on ice,
the resulting crude suspension was cleared by centrifuga-
tion for 20min at 10000g.
Raji cells were grown in RPMI 1640 medium containing
10% calf serum. Cos-1 cells, grown as monolayers in
Dulbecco medium supplemented with glucose (1g/l) and
5% fetal calf serum, were transfected with recombinant
plasmids, 8h after plating, using ExGen 500 reagent
(Euromedex, France) (23), with the amounts of recombi-
nant DNA indicated in the ﬁgure legends. After 48h, cells
were harvested in PBS and resuspended in lysis buﬀer
(0.4M KCl, 20mM Tris-HCl, pH 7.5, 20% glycerol,
5mM dithiothreitol, 0.4mM PMSF, 2.5ng/ml each of
leupeptin, pepstatin, aprotinin, antipain and chymosta-
tin). After one freeze–thawing cycle in liquid nitrogen, the
resulting crude suspension was cleared by centrifugation
for 20min at 10000g (24).
Antibodies
Rabbit antisera against ATF7, and monoclonal antibodies
speciﬁcally recognizing the ATF7 isoforms (2F10, 1A7,
3C12), GFP (2A5) GST (1D10), FLAG (M2) and HA
epitopes (12CA5) have been described (13,14). Rabbit
antisera against RanBP2 (PA1-082) was purchased from
Aﬃnity BioReagen. Rabbit antisera against SUMO-1 was
a gift from Dr Jacob Seeler (Institut Pasteur, Paris).
The monoclonal antibody against Nuclear Pore Complex
proteins (mAb414) was a kind gift from V. Doye (Institut
Curie, Paris).
Invitro SUMO-1 conjugation
The SUMO-1 conjugation assay was previously
described (25). Brieﬂy, this assay was performed in a
system containing an ATP-regenerating system
(50mM Tris-HCl, pH 7.6, 5mM MgCl2, 10mM
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ml inorganic pyrophosphatase, 2mM ATP). Twenty-
microliter reactions contained 100 ng of puriﬁed recombi-
nant hsSAE1/2 (E1), 400ng of puriﬁed recombinant
hsUbc9 (E2), 1mg of puriﬁed recombinant human
6His:Myc:SUMO-1(1–97) and either 100ng puriﬁed
recombinant protein substrate (ATF7) or 5mlo fin vitro
transcription/translation-coupled reactions (ATF2) (10).
Reactions were incubated at 378C for 1–2h.
NiNTA-agarose affinity chromatography and
immunoblotting
Aliquots of cell extracts were incubated (1h at 48C) with
50ml of a NiNTA-agarose bead suspension (Qiagen) in
PBS. The beads were washed three times with 1ml of PBS,
0.5% Nonidet P-40 and NaCl adjusted to 250mM. The
proteins were then dissociated by boiling for 5min in 20ml
sample buﬀer, before SDS-10% polyacrylamide gel
electrophoresis (SDS-PAGE). Protein analysis by western
blotting was carried out as described (13). Brieﬂy, proteins
were electrotransferred onto nitrocellulose, reacted with
speciﬁc primary antibodies (see above) and revealed with
peroxidase-linked goat anti-mouse Kappa-light chain
or goat anti-rabbit immunoglobulins (SantaCruz)
as indicated, using the ECL system (Amersham).
Luciferase assay
Transfected cells were harvested in ice-cold PBS, pelleted,
washed once in PBS and resuspended in lysis buﬀer
(100mM potassium phosphate, pH 7.8). After three
freeze–thawing steps in liquid nitrogen, the resulting cell
lysate was cleared by centrifugation. Aliquots of the
extracts (normalized by protein concentration) were
assayed for luciferase activity using a Berthold Centro
LB 960 luminometer, as previously described (26,27).
In all cases, at least ﬁve independent transfections
were carried out and the results always agreed within
10%. The results of typical experiments are shown in the
ﬁgures.
Electrophoretic DNA-binding assay
Gel-retardation experiments were performed as previously
described (28). Brieﬂy, about 0.3ng (5000cpm) of a
32P-50-end-labeled double-stranded oligonucleotide probe
was incubated with the cell extract in the presence of poly
(dI-dC), poly (dI-dC) as non-speciﬁc competitor and 1mg
of anti ATF7(3C12) monoclonal antibody when indicated.
For competition experiments, the protein fractions were
preincubated with 50ng of unlabeled oligonucleotides
before addition of the labeled probe. After 10min at 258C,
the complexes were separated by electrophoresis on a
non-denaturing 4.5% polyacrylamide gel.
RNA expression analysis (RT–PCR)
Total RNA was extracted using TRIzol reagent. One
microgram of puriﬁed total RNA was used for RT–PCR
analysis using the Transcriptor First Strand CDNA
Synthesis Kit (Roche Diagnostics GmbH). For PCR
reaction, 25 cycles were performed (denaturation: 958C,
1min; annealing: 608C, 2min; polymerization: 688C,
2min). PCR products were separated onto agarose gels
and DNA was visualized by ethidium bromide staining.
Primers for E-selectin RNA ampliﬁcation were designed
according to the E-selectin mRNA sequence published
[NCBI Nucleotide GenBank (accession number: NM-
000450) 50-primer: 50-TCTCTCAGCTCTCACTTTG-30,
30-primer: 50-TTCTTCTTGCTGCACCTCT-30].
E-selectin PCR product is 383bp in length. Primers for
b-actin ampliﬁcation (367bp PCR product) were as
follows: 50-primer: 50-CTCACCATGGATGATGATAT-
30 and 30-primer: 50-TGGGTCATCTTCTCGCGGTT-30.
ChIP and quantitative real-time PCR
HeLa-SUMO cells were transfected with either
px-ATF7WT px-ATF7K118R or px-SUMO-GA-
ATF7K118R vectors. Forty-eight hours after transfection,
ChIP assays were performed using a ChIP Assay Kit
(Upstate Biotechnology, USA), following the manufac-
turer recommendations.
Quantitative real-time PCR was performed on
LightCycler (Roche Diagnostics, Switzerland), as speciﬁed
by the manufacturer, using LightCycler FastStart DNA
Master SYBR Green I reagents with 45 cycles of three-
step ampliﬁcation. The 50 to 30 sequences of the primers
used in the PCR were: Fwd: GTCATATTAATAAAATT
GCATATACGATAT; Rev:TCTCAGGTGGGTATCAC
TGCTGCCTCTGTC. After PCR, ampliﬁed DNA was
collected and migrated on 1% agarose gels.
Immunofluorescence
Immunoﬂuorescence staining experiments were carried
out as previously described (29). Brieﬂy, 48h after
transfection, HeLa-SUMO cells, grown on coverslips,
were ﬁxed with formaldehyde (4% [vol/vol] in PBS) and
permeabilized with 0.1% Triton X-100 in PBS. The
primary antibodies were diluted in PBS containing 0.1%
Triton X-100. Antibodies were used at the following
dilutions in PBS containing 0.1% Triton X-100: the anti-
ATF7 monoclonal (2F10 or 1A7) and polyclonal anti-
bodies were used both at 1/2000 dilution; the anti-RanBP2
and NCP4 antibody were used at 1/1000 dilution. After
incubation at 208C for 1h, the coverslips were washed
several times in PBS, 0.1% Triton X-100 and then
incubated 1h at 208C with donkey CY3-conjugated anti-
rabbit or anti-mouse IgG and/or donkey Alexa588-labeled
anti-rabbit IgG (Sigma), at concentrations recommended
by the suppliers. Nuclei were counterstained with Hoechst
33258. After the staining, the coverslips were mounted and
analyzed using a confocal laser-scanning microscope
(Leica). Image-enhancement software was used to balance
signal strength, and 8-fold scanning was used to separate
signal from noise.
Time laps experiments
For monitoring the nuclear import of the ATF constructs,
HeLa-SUMO cells were seeded on coverslips, grown for
24h, before mounting in a Life Imaging Services Ludin
Chamber kept at 378C, 5% CO2, placed in a Leica
DMIRE2 microscope equipped with a Life Imaging
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nuclear importation was triggered by addition of
dexamethasone (100mM) to the cell-culture medium.
Images were acquired every 25s during 15min, using a
Leica DC350FX CCD camera piloted by the Leica
FW4000 software. Eight ﬁelds (corresponding to a
minimum of 60 cells) were recorded during each experi-
ment by the use of a Marzhauser automated stage piloted
by the FW4000 software. To compare the intensity of
the ﬂuorescent signals in the cytoplasm and the nucleus,
the sequences were loaded in the Universal Imaging
Metamorph software, and average signal intensity were
recorded in regions selected in the perinuclear cytoplasm
and inside the nucleus. Signal intensity values were
transferred in Microsoft Excel where the cytoplasmic
and nuclear signals were compared. The equilibration
point refers to the time needed for each construct to reach
a signal intensity superior in the nucleus than in the
cytoplasmic perinuclear region.
RESULTS
ATF7 Sumoylation
To identify polypeptides that are able to interact with
the activation domain of ATF7 transcription factor,
a two-hybrid screen in yeast was performed to a mouse
cDNA fusion library, using the 60% N-terminal portion
of ATF7 as a bait. In this screening only the N-terminal
portion of ATF7 lacking the leucine-zipper (b-ZIP) was
chosen to avoid potential interactions with other b-ZIP-
containing molecules. Among the selected clones, one
corresponded to mBLM, a DNA helicase implied in the
Bloom Syndrome disease (30), another one to mAM (29)
a recently described protein shown to facilitate conversion
from dimethyl to trimethyl lysine 9 of histone H3 by ESET
and cause transcriptional repression (31). Interestingly,
a third one corresponded to Ubc9, the SUMO
E2-conjugating enzyme (32,33). In addition, protein
sequence analysis revealed that ATF7 contains a potential
sumoylation target site (I-K-X-E) matching the consensus
sequence (Figure 1A) (1,34,35). To investigate whether
ATF7 could be sumoylated, we ﬁrst used an in vitro assay
(Figure 1B). Puriﬁed bacterially expressed ATF7 proteins
were incubated with a minimal SUMO-1 conjugation
system composed of puriﬁed recombinant human E1
(SAE1/2), E2 (Ubc9) enzymes and puriﬁed mature
SUMO-1 (aa 1–97) (36,37). Immunoblot analysis revealed
an additional band of slower mobility when the ATF7
protein was the substrate (ATF7WT) but not when its
sumoylation site was mutated (ATF7K118R). As a
negative control, ATF2, a protein closely related to
ATF7 that lacks the consensus sumoylation site
(Figure 1A), was shown not to be sumoylated in this
assay (Figure 1B).
Detection of SUMO-1 conjugates in living cells is often
diﬃcult because only a small proportion of cellular
SUMO-1 target proteins is modiﬁed at any given time.
For this reason, SUMO conjugation is generally investi-
gated using cells overexpressing SUMO proteins.
To verify SUMO-1 modiﬁcation of ATF7 in a cellular
context, we thus transfected a human cell line
(HeLa-SUMO) that constitutively expresses elevated
levels of 6His:Myc:epitope-tagged human SUMO-1
protein (22) with plasmids expressing either the
ATF7WT or the K118R derivative (Figure 1C).
Transfected cells were lysed in the presence of SDS and
N-ethylmaleimide (NEM) to inhibit SUMO-speciﬁc
proteases activity. Cellular extracts were passed over
nickel-charged agarose resin (Ni-NTA agarose, Qiagen)
to purify 6His:Myc:SUMO-1 conjugated proteins.
Analysis of Ni-NTA bound fractions was ﬁrst performed
by immunoblotting using SUMO-1 speciﬁc antibodies
(Figure 1C, left panel). Ladders of many SUMO
conjugated proteins retained on the Ni-NTA beads
could be observed, but interestingly a major band with
an apparent molecular weight compatible with that of a
mono-sumoylated form of ATF7 was detected only into
the cells transfected with ATF7WT. The same blot was
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Figure 1. SUMO-1 modiﬁcation of recombinant ATF proteins. Peptide
sequence alignments between ATF7 and ATF2. (A) Amino acid
sequences (one-letter code) of relevant portions of the proteins are
given, below the consensus sumoylation target site (, hydrophobic
residues; X, any residue). Bold-faced characters represent potential
sumoylation sites, with respective coordinates. (B) Puriﬁed bacterially
expressed ATF7 WT (lanes 3 and 4), ATF7 K118R (lanes 1 and 2)
and in vitro synthesized
35S-labeled ATF2 (lanes 5 and 6) were
subjected to in vitro SUMO-1 conjugation, as indicated (System
refers to the complete assay reaction as described in Materials and
Methods—AU refers to arbitrary unit). Reaction products were
analyzed by SDS-PAGE, followed by immunoblotting using ATF7
(2F10) monoclonal-antibodies (lanes 1–4) or autoradiography (lanes 5
and 6). (C) HeLa-SUMO cells were transfected with 0.5mg px-
ATF7WT or pXATFK118R. Extracts (500mg) from transfected cells
were passed through Ni-NTA agarose (aﬃnity-puriﬁcation). Proteins
were separated by SDS-PAGE and the presence of sumoylated ATF7,
and then ATF7 was revealed by western blotting (WB) using speciﬁc
antibodies, as indicated. (D) Extracts (500mg) from Raji cells were
immunoprecipitated with the anti-ATF7 (2F10) antibodies. Proteins
were separated by SDS-PAGE and the presence of ATF7, and then
sumoylated ATF7 was revealed by western blotting (WB) using speciﬁc
antibodies, as indicated.
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both cell-extracts the presence of similar amounts of
non-modiﬁed ATF proteins that also bind to the resin
through their zinc-binding domain (Figure 1C, right
panel). Together these results clearly demonstrate that
the mutation K118R impairs the symoylation of ATF7.
To demonstrate that the endogenous ATF7 proteins are
covalently modiﬁed by SUMO in vivo, we used Raji cells,
a human lymphoid cell line in which ATF7 is naturally
more abundant than in other cell lines (14). Cells were
lysed in the presence of SDS and N-ethylmaleimide
(NEM) to inhibit SUMO-speciﬁc proteases activity.
The cellular extracts were immunoprecipitated using
monoclonal anti-ATF7 antibodies and analyzed by
western blotting using ﬁrst ATF7 antibodies (Figure 1D,
left panel). A major band corresponding to ATF7 was
observed. Interestingly, a minor band with an apparent
molecular weight compatible with that of a mono-
sumoylated form of ATF7 was also detected. To assess
the speciﬁcity of this band, the same blot was then probed
with anti SUMO-1 polyclonal antibodies. As shown
in Figure 1D (right panel), the SUMO-1 antibodies
speciﬁcally recognized the upper band. Thus the endo-
genous ATF7 proteins are subjected to modiﬁcation by
SUMO-1 in vivo.
SUMO-1modification affects ATF7 intracellular
localization
Previous studies had correlated SUMO modiﬁcation
with the recruitment of target proteins to specialized
subnuclear domains, (1–3,34,35,38). To address this issue,
we transiently expressed ATF7WT and ATF7K118R
mutant into HeLa-SUMO cells and followed their
intracellular localization by ﬂuorescence microscopy.
Immunostaining of transfected cells with anti-ATF7
antibody revealed two patterns of localizations: 90% of
the transfected cells mainly showed a nuclear localization
for ATF7WT, with a diﬀuse distribution excluding the
nucleoli (Figure 2A) while 10% of the transfected cells
showed a distinct pattern restricted to the periphery of the
nucleus (Figure 2B). On the other hand, expression of
ATF7K118R proteins that cannot be sumoylated showed
exclusively the nucleoplasmic localization pattern
(Figure 2C). These results suggest that sumoylation may
trap the protein at the vinicity of the nuclear envelope.
In order to check this hypothesis, we engineered a
constitutively sumoylated form of ATF7 by covalently
attaching SUMO-1 to ATF7 by gene fusion as previously
described for Sp3 or TAF5 (25,39). We therefore
generated a ATFK118R derivative composed of the
protein SUMO-1 (amino acids 1–96) directly fused
N-terminus of ATF7. The C-terminal Gly of full-length
SUMO-1 was replaced by an Ala in order to prevent
cleavage of the fusion proteins by C-terminal SUMO
hydrolases (39). As shown in Figure 2D and E, 20% of
the cells transfected with this construct displayed an
immunoﬂuorescence staining localized at the periphery of
the nucleus. This represents a 2-fold increase compared
to the number observed with wild-type ATF7.
The observation that not all the cells showed such a
perinuclear localization pattern suggests that sumoylation
may only transiently block the protein at this level.
RanBP2 functionsas aSUMO E3ligasefor ATF7
The observed perinuclear localization of the sumoylated
form of ATF7 proteins strongly suggests that the
corresponding modiﬁcation process may occur during
their entry into the nucleus. Since it has been shown
that the nuclear pore complex (NPC) RanBP2 protein
strongly enhances SUMO-1 modiﬁcation of the nuclear
body-associated SP100 protein (40) and HDAC4 deace-
tylase (41), we tested whether this protein could function
as a SUMO E3 ligase for ATF7. To verify this hypothesis,
our reconstituted in vitro modiﬁcation assay (see Figure 1)
was performed with recombinant ATF7 in the presence
or absence of a bacterially produced RanBP2 fusion
protein (GST-RanBP2iFG). This truncated protein was
previously described to exhibit an E3 ligase activity (40).
As shown in Figure 3A, although the sumoylation of
ATF7 occurred to some extent in the absence of SUMO
ligase (lane 3), the reaction was strongly stimulated by
addition of the RanBP2 derivative (lane 5). To conﬁrm the
ATF7WT
A
B
C
D
E
Anti-ATF7 DNA Merge
SUMO-GA-
ATF7K118R
ATF7K118R 100%
80%
20%
90%
10%
Figure 2. Localization of ATF7 is regulated by SUMO-1.
HeLa-SUMO cells were transfected with plasmids encoding wild-type
ATF7 (WT, rows A and B) or mutated ATF7 (K118R, row C; SUMO-
GA-ATF7 K118R, rows D and E), as indicated. At 36h post-
transfection, cells were processed for immunostaining with monoclonal
anti-ATF7 antibodies (2F10) and donkey Cy3-labeled anti-mouse IgG.
Nuclei were counterstained with Hoechst 33258. Bar, 10nm.
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RanBP2 in a similar in vitro modiﬁcation experiment.
PIAS1 also exhibits E3 ligase activity but directed towards
diﬀerent transcription factors, like c-jun or p53 (42,43).
Whereas sumoylation of ATF7 was greatly enhanced by
RanBP2, PIAS1 failed to catalyze SUMO modiﬁcation of
ATF7 in a parallel reaction (data not shown). These
observations support the conclusion that RanBP2 func-
tions as a speciﬁc SUMO E3 ligase towards ATF7.
We next analyzed the ability of the fusion SUMO-GA-
ATF7 and RanBP2 proteins to interact within a
cellular context. To that end, HeLa-SUMO cells were
transfected with plasmids expressing either px-ATF7WT,
px-ATF7K118R, px-SUMO-GA-ATF7K118R and px-
HA-RanBP2 FG (Figure 3B). Whole cell extracts were
then submitted to immunoprecipitation (IP) with anti-
bodies against ATF7 and the precipitated proteins were
analyzed by western blotting using anti-HA antibodies.
As shown in Figure 3B, RanBP2 was detected in the
immunoprecipitates only when coexpressed with the
constitutively sumoylated ATF7 construct, but not in
the presence of ATF7WT or ATF7K118R. Therefore,
these results strongly suggest that sumoylation promotes
the interaction between ATF7 and RanBP2, supporting
the idea that RanBP2 is the ATF7 speciﬁc E3 ligase.
The fact that no interaction could be detected between
ATF7WT and RanBP2 can be explained by a very
low amount of the sumoylated ATF7WT protein in
HeLa-SUMO-transfected cells.
In order to reﬁne the location of sumoylated ATF7
within the nucleus of transfected cells, we performed
co-localization experiments using antibodies against
nuclear pore complex proteins (anti-NPC) and ATF7
(Figure 3C).
As expected, the anti-NPC antibodies primarily stained
the nuclear membrane. While the non-sumoylatable ATF7
derivative (ATF7K118R) was clearly nucleoplasmic
(row b), the ATF7 WT (row a) and its constitutively
sumoylated derivative (SUMO-GA-ATF7K118R; row c)
were conﬁned to the nuclear periphery, within up to 20%
of the transfected cells, in agreement with the results
shown in Figure 2. Furthermore, as revealed by the double
immunostaining, these ATF7 proteins clearly accumulate
in close proximity to the nuclear membrane, in a region
documented to be transcriptionally inactive (4).
Sumoylationdelays the entry into thenucleus
The results of our immunoﬂuorescence experiments
suggest that the entry of ATF7 into the nuclei is a
dynamic phenomenon which may be modulated by
sumoylation. In order to visualize ATF7 diﬀusion into
the nucleoplasm more precisely, time laps microscopy
experiments using GFP-tagged constructs were per-
formed. We used hormone-inducible GFP-tagged
chimeric ATF7 protein (ATF7-GR-GFP) (Figure 4A)
to study the ATF7 nuclear import in living cells. The ﬁrst
250 amino acid residues of ATF7 (to delete the ATF7
endogenous NLS sequence) were fused to the hormone-
responsive element from the glucocorticoid receptor–GFP
(GFP-GR) chimera.
To assess the eﬀect of sumoylation, the import of
ATF7WT, ATFK118R and SUMO-GA-ATF7K118R
GR-GFP derivatives was examined in HeLa-SUMO cells
(Figure 4B). In the absence of steroid, the chimeric
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Figure 3. Nuclear-membrane markers co-localize with ATF7.
(A) Puriﬁed bacterially expressed ATF7WT was subjected to in vitro
SUMO-1 conjugation, in the presence or in the absence of puriﬁed
bacterially expressed GST-RanBP2. Reactions in lanes 4–5 were
performed with 20-fold less in vitro sumoylation reaction mix
(System) than in lanes 1–3. Reaction products were analyzed by
SDS-PAGE and by immunoblotting using ATF7 antibodies. (B) HeLa-
SUMO cells were transfected with 0.5mg px-ATF7 derivatives and
px-HA-RanBP2iFG as indicated. Extracts from transfected cells were
immunoprecipitated (IP) with the anti-ATF7 (2F10) monoclonal
antibodies as described in Materials and Methods. The puriﬁed
complexes were separated by SDS-PAGE. The presence of
HA-RanBP2iFG proteins in both IP and extracts, and ATF7
derivatives in the extracts was revealed by western blotting (WB)
using speciﬁc antibodies. (C) HeLa-SUMO cells were transfected
with plasmids encoding mutated ATF7WT (a), ATF7 K118R (b)
or SUMO-GA-ATF7 K118R (c), as indicated. At 36h post-
transfection, cells were processed for immunostaining with monoclonal
anti-ATF7 antibodies (2F10) and donkey Alexa488-labeled anti-
mouse IgG or rabbit polyclonal anti-NPC and donkey Cy3-labeled
anti-rabbit IgG. Nuclei were counterstained with Hoechst 33258.
Bar: 10nm.
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tion of the three variants into the nucleus was observed
only after the addition of dexamethasone (Figure 4B).
For each construct, we measured the mean time required
to reach a nuclear signal of same intensity as the one
observed in the cytoplasmic perinuclear region. Clearly,
constitutively sumoylated ATF requires twice as much
time as the other proteins to equilibrate the nuclear signal
to the level of the cytoplasm. This indicates that
sumoylation speciﬁcally delays the import of the ATF7
protein into the nucleus.
Sumoylationof ATF7 interferes withits transcriptional
activity
To get an insight of the eﬀect of sumoylation on the
transcriptional activation mediated by ATF7, we analyzed
the eﬀect of K118R mutation speciﬁcally impairing
the sumoylation of ATF7 on its transcriptional activity.
We investigated the interplay of this modiﬁcation using
the Gal4 protein fusion system (44), in which the ATF7
protein is linked to the yeast Gal4 DNA binding domain
(1–147). The activity of the chimeric products was
assayed in cotransfection experiments with a luciferase
reporter gene whose promoter contained ﬁve Gal4 binding
sites (44). Cos-1 cells were transfected with the pG4-ATF7
vector or derivatives and the luciferase reporter.
The results of a typical experiment are shown in
Figure 5A. The K118R mutant stimulated transcription
of the reporter gene 2-fold more than the WT protein.
In contrast, the Gal4-SUMO-GA-ATF7 K118R construc-
tion was about 4-fold less active than the WT protein
while equal levels of Gal-ATF7 fusions were expressed
and showed identical cellular distribution as the non-fused
proteins. These results indicate that a large part of the WT
protein activity is due to its non-sumoylated form.
Identical results were obtained with the three ATF7
isomers (9), namely ATF7-1, ATF7-2 and ATF7-3 (not
shown). Thus sumoylation plays a negative role in the
ATF7-induced transactivation process under these experi-
mental conditions, possibly by sequestering the proteins in
the periphery of the nucleus.
We previously showed that the transcriptional activity
of ATF7 is potentiated by expression of TAF12 and
that the two proteins are interacting in vivo (14). We
investigated the ability of the fusion SUMO-GA-ATF7
and TAF12 proteins to interact within a cellular
context. To that end, HeLa-SUMO cells were trans-
fected with plasmids expressing p-hsTAF12 together
with px-ATF7, px-ATF7K118R and px-SUMO-GA-
ATF7K118R (Figure 5B). Whole cell extracts were then
submitted to immunoprecipitation (IP) with antibodies
against ATF7, and the precipitated proteins were analyzed
by western blotting using anti-TAF12 antibodies. As
shown in Figure 5B (lanes 1–4), TAF12 was detected in
the immunoprecipitates only when coexpressed with
ATF7WT or ATF7K118R, but not when coexpressed
with the constitutively sumoylated ATF7 construct.
In HeLa-SUMO transfected cells, the majority of the
overexpressed ATF7WT protein is not sumoylated.
Therefore, these results strongly suggest that sumoylation
may prevent the interaction between ATF7 and TAF12,
and this loss of interaction would thus account for the
transcriptional inhibitory eﬀect of ATF7 sumoylation. To
gain some insight into the molecular mechanism of this
diﬀerential action on transcription, we ﬁrst performed a
chromatin immunoprecipitation (ChIP) experiment on the
E-selectin gene. ATF7 has previously been shown to
speciﬁcally bind to the NF-ELAM1 promoter element of
the E-selectin gene and to interact with TAF12 (14).
HeLa-SUMO cells were transfected with vectors expres-
sing either ATF7WT, K118R ATF7, or SUMO-GA-
ATF7K118R under conditions where equal levels of
proteins were expressed, as veriﬁed by immunoblotting
with speciﬁc antibodies (Figure 6A). We also checked by
gel-shift assays that the three proteins were able to bind
the NF-ELAM1 promoter element with very similar
eﬃciencies (Figure 6B). As shown in Figure 6A, the
E-selectin promoter was immunoprecipitated more eﬃ-
cently in ATF7K118R expressing cells than in ATF7WT
or SUMO-GA-ATF7K118R transfected cells. These
results clearly indicate that, in the context of a natural
promoter (and in a steady-state level), non-sumoylated
ATF7 form is more strongly associated with the chroma-
tin. Therefore sumoylation prevents the association of
ATF7 with the target promoter or facilitates its removal
in vivo. In addition, a direct measurement of transcription
was performed to analyze the changes in an ATF7
target gene expression upon the changes in ATF7
sumoylation. RT-PCR analysis clearly shows that
transcription of the E-selectin gene is enhanced in the
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Figure 4. Sumoylation delays protein entry into the nucleus.
(A) The structures of the diﬀerent ATF7 constructs are schematized.
(B) Time laps microscopy monitoring of cells expressing GFP
fused constructs ATF7WT, ATF7K118R or SUMO-GA-ATF7.
HeLa-SUMO cells were transfected with 0.25mg of the diﬀerent
plasmids as indicated. Twenty-four hours later 10nM Dexamethasone
was added to the culture medium (t¼0). The level of ﬂuorescence in
the nucleus was monitored using time laps microscopy. Bar: 20nm.
Quantiﬁcation of the mean time required to reach a nuclear signal of
same intensity as the one measured in the cytoplasm perinuclear region
(cytoplasm/nuclear equilibration). Constitutively sumoylated ATF
requires twice as much time as the other constructs to equilibrate the
nuclear signal to the level of the cytoplasm.
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sion level of the control gene (b-actin) is unaﬀected.
Altogether, these observations clearly conﬁrm the inhibi-
tory eﬀect of sumoylation of ATF7 on the transactivation
process: sumoylation not only impairs the interaction
between ATF7 and TAF12 but blocks the access of ATF7
to promoters.
DISCUSSION
Small ubiquitin-like modiﬁer (SUMO) modiﬁcation has
emerged as an important regulator of diverse pathways
and activities including protein targeting, transcriptional
regulation, modulation of enzyme activity and protein
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Figure 5. Sumoylation aﬀects ATF7 transcriptional activity. (A) HeLa-SUMO cells were co-transfected with 0.25mg of the pG4-ATF7 expression
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were transfected with 0.5mg px-ATF7 derivatives and hsTAF12. Extracts from transfected cells were immunoprecipitated (IP) with the anti-ATF7
(2F10) monoclonal antibody as described in Materials and Methods. The puriﬁed complexes were separated by SDS-PAGE. The presence of
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present article, we demonstrate that the ATF7 transcrip-
tion factor is sumoylated in vitro and in vivo, and that
sumoylation aﬀects its intranuclear localization and its
transcriptional activity by impairing the interaction
between ATF7 and TAF12, thereby blocking the access
of ATF7 to its speciﬁc promoters.
ATF7, butnot ATF2, issumoylated
Since their discovery, ATF7 and ATF2 although encoded
by distinct genes (9,45) have always been described as two
closely related proteins, with very similar properties (7,46).
For example, the two proteins mediate transactivation by
the adenovirus oncoprotein E1a (8,47) and heterodimerize
with Jun or Fos proteins (10). They are also phoshorylated
by p38 and JNK MAP-kinases (11,48,49) and their
transcriptional activity is mediated by TAF12 (14).
By contrast, a survey of the protein sequences derived
from all sequenced eukaryotic genomes clearly reveals a
consensus sumoylation site (fKXE) within all known
ATF7 protein sequences, whereas it is absent in all ATF2
proteins. We clearly show here that ATF7, but not ATF2,
is sumoylated in vivo at the lysine residue (K118)
belonging to this element. Though this sequence is located
in the previously described transactivating domain, it is
the ﬁrst time that such a striking diﬀerence is observed
between the activity of the two proteins. This indicates
that, notwithstanding their high functional and structural
homologies, these two ATF proteins likely play distinct
roles in the cell.
It has been suggested that SUMO modiﬁcation could
aﬀect the subcellular localization of proteins (3). As shown
for many nuclear proteins, sumoylation can direct some
transcription factors to the so-called PML nuclear
bodies (50), thus sequestering them away from the DNA
and taking them out of action (50–52). Furthermore,
sumoylation can also be coupled with the transport of
proteins between the cytoplasm and the nucleus (53,54).
As revealed by our localization studies, the wild-type
ATF7 (ATF7WT) is dispersed throughout the nucleo-
plasm in the majority of the cells (about 90%), while it is
restricted to a perinuclear distribution in approximately
10% of the cells. The fact that a non-sumoylatable mutant
protein (ATF7K118R) never accumulates at the nuclear
periphery, strongly suggests that the nucleoplasmic ATF7
corresponds to the non-sumoylated fraction of the
protein. On the other hand, the in vivo perinuclear
localization is in good agreement with the fact that the
ATF7 sumoylation process requires (i) Ubc9, a conjugat-
ing enzyme which is associated to both cytoplasmic and
nucleoplasmic ﬁbrils of the nuclear pore complex (NPC)
in vivo (55), and (ii) the E3 ligase RanBP2, a protein
also belonging to the NPC (40). Thus, it appears that
the ATF7 localization is aﬀected by sumoylation, as
previously reported for other transcription factors,
like Sp3 (39), CtBP (56), Elk-1 (57) or SATB2 (58).
In the latter case, a very similar correlation between
sumoylation and subnuclear localization has also
been observed: sumoylated SATB2 was predominantly
localized at the nuclear periphery, whereas a sumoylation-
deﬁcient SATB2 protein had a more diﬀuse nuclear
localization (58).
Our results clearly indicate that sumoylation does not
block the nuclear entry of ATF7 since a constitutively
sumoylated ATF7 derivative (SUMO-GA-ATF7K118R)
exhibits a distribution pattern similar to the WT protein,
as revealed by classical immunoﬂuorescence microscopy
experiments based on snapshot pictures of ﬁxed cells.
Time laps microscopy further extended our views. Indeed,
the stably sumoylated protein takes twice as long as the
non-sumoylated form (ATF7K118R) to enter the nucleus
and evenly to redistribute over the nucleoplasm. These
kinetic experiments strongly suggest that ATF7 sumoyla-
tion is a dynamic process that aﬀects its in vivo localization
behavior. Thus an equilibrium between the relative
amounts of sumoylated and non-sumoylated forms of
the protein might exist in the cell.
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Figure 6. Sumoylation aﬀects ATF7 activity. (A) ChIP analysis of
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promoter DNA, coprecipitated with the indicated antibodies, was
detected by PCR. (B) Recombinant pSG5-based vectors (0.5mg)
directing the expression of the various chimeras were transfected into
HeLa-SUMO cells, and cell lysates were analyzed by EMSA: 20mgo f
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1142 Nucleic Acids Research, 2007, Vol. 35, No. 4Sumoylation affects ATF7 transcriptional activity
Besides its contribution to the subcellular localization of
ATF7, a functional role for the sumoylation was inferred
from the analysis of the SUMO-deﬁcient mutant protein
(ATF7K118R). First, chromatin immunoprecipitation
experiments revealed that the SUMO-deﬁcient mutant
ATF7 derivative associates more eﬃciently than
ATF7WT with the CRE promoter element of the
endogenous E-selectin gene. Second, SUMO-deﬁcient
ATF7 stimulated expression from a cotransfected reporter
plasmid more eﬃciently than ATF7WT. By contrast,
fusion of SUMO to the K118R mutant of ATF7 (as in
SUMO-GA-ATF7K118R) resulted in a decrease of its
transcriptional activation potential, an observation most
likely related to the negative eﬀect of SUMO on the ability
of ATF7 to interact with its TAF12 partner. As previously
shown, TAF12 potentiates ATF7-induced transcriptional
activation through direct interaction with the N-terminal
ATF7 transactivation domain (14). It appears therefore
that the SUMO modiﬁcation clearly contributes to the
regulation of the ATF7 transcriptional activity by
impairing the interaction between ATF7 and TAF12.
Interestingly, both TAF5 and TAF12—TFIID subunits—
have been shown to be sumoylated (25). However, only
SUMO conjugation of TAF5 interferes with binding of
TFIID to promoter DNA, whereas modiﬁcation of
TAF12 has no detectable eﬀect in this respect.
Furthermore, SUMO conjugation has also no detectable
eﬀect on nuclear import or intranuclear distribution of
these two TAFs. Clearly sumoylation may diﬀerentially
aﬀect proteins involved in a same function, i.e. transacti-
vation of target genes. It is diﬃcult to directly correlate the
functional diﬀerences observed between native ATF7WT
and its non-sumoylatable counterpart (ATF7K118R),
in terms of transcriptional activity or occupation of its
target promoters, with their actual respective sumoylation
levels. Indeed, the action of endogenous SUMO proteases
(Senp1 and/or 2), released into the cell extracts, likely
alters the apparent proportion of sumoylated proteins.
This is best illustrated in Figure 5, where ATF7WT and
ATF7K118R exhibit signiﬁcantly diﬀerent transcriptional
and promoter binding activities (panels A and D), while
showing equally low levels of sumoylation, compared to
the Senp-resistant SUMO-GA-ATF7K118R derivative
(panel B). A model has recently been proposed (4),
in which the pool of sumoylated transcription factors
constitutes a built-in portion of more general transcrip-
tional repression complexes. Within these structures,
factors could be desumoylated while remaining associated
with the complex of repression, independent of SUMO.
Thus, SUMO would be required to initiate but not to
maintain repression (4). However, upon sustained
desumoylation, the overall number of repression com-
plexes might ultimately decrease. Such a scenario has
been described in the case of the Elk-1 transcription
factor whose phosphorylation by MAP-kinases is con-
comitant with its desumoylation and the activation of
transcription (59). The fact that transcriptional activity of
ATF7 is enhanced when the p38 MAP-kinase pathway is
stimulated supports this model. Consequently, it would be
advisable to check the relationships between phosphoryla-
tion and sumo/desumoylation of ATF7.
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